MART-1 Antigen
-
Subject Areas on Research
- Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain.
- CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
- Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
- Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.
- Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
- Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
- Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
- Immune selection after antigen-specific immunotherapy of melanoma.
- Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
- Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.
- Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.
- Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
- Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR.
- Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
- Short-term kinetics of tumor antigen expression in response to vaccination.
- Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.
- Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.